Together, these studies indicate that enhancers occupied by ER⍺, FOXA1, and GATA3 frequently also bind GRHL2, but a majority of conserved GRHL2 binding sites in luminal breast cancer cells do not overlap with binding of the ER⍺ signaling complex. This evidence concerns the gene FOXA1 and breast carcinoma.